146 related articles for article (PubMed ID: 34634528)
21. HPLC detection of miltefosine using an evaporative light scattering detector.
Lemke A; Kayser O
Pharmazie; 2006 May; 61(5):406-8. PubMed ID: 16724535
[TBL] [Abstract][Full Text] [Related]
22. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
23. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
24. Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.
Shao Y; Xie S; Zhu H; Du X; Xu RA
J Pharm Biomed Anal; 2020 Aug; 187():113355. PubMed ID: 32442869
[TBL] [Abstract][Full Text] [Related]
25. Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography.
Knebel NG; Grieb S; Winkler M; Locher M; van der Vlis E; Verheij ER
J Chromatogr B Biomed Sci Appl; 1999 Jan; 721(2):257-69. PubMed ID: 10052698
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
Castro MD; Gomez MA; Kip AE; Cossio A; Ortiz E; Navas A; Dorlo TP; Saravia NG
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956421
[TBL] [Abstract][Full Text] [Related]
27. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Katara GK; Verma S; Salotra P
Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437
[TBL] [Abstract][Full Text] [Related]
28. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
[TBL] [Abstract][Full Text] [Related]
29. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
30. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
Sundar S; Singh A; Chakravarty J; Rai M
ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
[TBL] [Abstract][Full Text] [Related]
32. Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
Jaiteh MB; İnkaya AÇ; Üner A; Elçin G; Ergüven S; Kurtulan O; Harxhi A; Akova M
Parasitol Int; 2021 Feb; 80():102197. PubMed ID: 32920054
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation.
Moreno-Vicente R; Fernández-Nieva Z; Navarro A; Gascón-Crespí I; Farré-Albaladejo M; Igartua M; Hernández RM; Pedraz JL
J Pharm Biomed Anal; 2015 Oct; 114():105-12. PubMed ID: 26037158
[TBL] [Abstract][Full Text] [Related]
34. Indacaterol determination in human urine: validation of a liquid-liquid extraction and liquid chromatography-tandem mass spectrometry analytical method.
Ammari WG; Al-Qadhi Z; Khalil M; Tayyem R; Qammaz S; Oriquat G; Basheti IA; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):202-10. PubMed ID: 25229261
[TBL] [Abstract][Full Text] [Related]
35. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
[TBL] [Abstract][Full Text] [Related]
36. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
37. Laser diode thermal desorption atmospheric pressure chemical ionization tandem mass spectrometry applied for the ultra-fast quantitative analysis of BKM120 in human plasma.
Lanshoeft C; Heudi O; Leuthold LA; Schlotterbeck G; Elbast W; Picard F; Kretz O
Anal Bioanal Chem; 2014 Sep; 406(22):5413-23. PubMed ID: 24958346
[TBL] [Abstract][Full Text] [Related]
38. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
